Anaplastic Astrocytoma Market Size In 2026: Growth Outlook And Forecast Through 2030
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Anaplastic Astrocytoma Market Growth Potential: How Will Market Size Shift Through 2030?
The anaplastic astrocytoma market has experienced significant expansion in recent years. It is anticipated to increase from $0.46 billion in 2025 to $0.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.1%. This historical growth can be attributed to advancements in brain tumor diagnostics, the accessibility of neurosurgical treatment options, the expansion of oncology treatment centers, increased participation in clinical trials, and the rising utilization of radiotherapy.
The anaplastic astrocytoma market is predicted to experience significant expansion in the coming years, with its size projected to reach $0.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the forecast period stems from various factors such as increased investments in neuro-oncology research, a rise in the adoption of precision medicine strategies, the expansion of targeted and adjunct therapies, an intensified focus on early detection methods, and growing collaboration among research institutions. Furthermore, prominent trends expected in this timeframe include the increasing embrace of multimodal treatment approaches, the rising utilization of advanced neuroimaging tools, a stronger emphasis on personalized oncology therapies, an expansion of clinical research initiatives, and better integration of surgical and radiotherapy protocols.
Get A Free Sample Report With In-Depth Market Insights:
Anaplastic Astrocytoma Market Development Factors: What’s Supporting Demand?
The increasing occurrence of primary malignant and non-malignant brain tumors is anticipated to drive expansion in the anaplastic astrocytoma market. These brain growths are categorized into cancerous (malignant) and invasive types, or non-cancerous (benign) and non-invasive types, exhibiting diverse levels of aggressiveness and capacity for dissemination. Treatment for anaplastic astrocytoma involves the excision of the tumor along with the adjacent affected tissue, all while maintaining brain functionality. As an illustration, in March 2023, data from the American Society of Clinical Oncology (ASCO), a US-based non-profit organization, projects that approximately 24,810 adults in the United States will be diagnosed with primary cancerous tumors beginning in the brain and spinal cord, comprising 14,280 cases among men and 10,530 among women. Consequently, the rising prevalence of primary malignant and non-malignant brain tumors will fuel the expansion of the anaplastic astrocytoma market in the future.
Anaplastic Astrocytoma Market Segment Analysis Spotlighting Growth Areas
The anaplastic astrocytoma market covered in this report is segmented –
1) By Treatment Type: Surgery, Chemotherapy, Radiation Therapy
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Specialty Cancer Centers
Subsegments:
1) By Surgery: Maximal Safe Tumor Resection, Stereotactic Biopsy
2) By Chemotherapy: Alkylating Agents, Targeted Therapy
3) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT)
Anaplastic Astrocytoma Market Transformation Trends: What Innovations Are Driving Change?
Key players within the anaplastic astrocytoma market are concentrating on creating sophisticated combination treatments aimed at improving both overall survival and progression-free survival for individuals experiencing recurrent forms of the disease. This therapeutic approach utilizes multiple drugs concurrently to address cancer pathways, thereby boosting treatment effectiveness and slowing down tumor advancement. As an illustration, in November 2024, Orbus Therapeutics, a biopharmaceutical firm based in the US, introduced a novel combination of eflornithine and lomustine as part of its Phase 3 STELLAR study. This treatment demonstrated significant clinical enhancements in overall survival and progression-free survival among patients suffering from grade 3 IDH mutant astrocytoma. Noteworthy outcomes comprised a median overall survival of 34.9 months, significantly higher than the 23.5 months observed with lomustine alone, alongside a median progression-free survival of 15.8 months compared to 7.2 months, and an overall favorable safety profile. The therapy’s mechanism relies on eflornithine’s capacity to irreversibly block ornithine decarboxylase, a crucial enzyme involved in polyamine biosynthesis, thereby amplifying its cytostatic action. Encompassing over 343 patients across North America and Europe, the study showcased considerable clinical advantages within a challenging patient group, thus presenting a hopeful new alternative for individuals with recurrent anaplastic astrocytoma.
Anaplastic Astrocytoma Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb, AstraZeneca, Eli Lilly and Company, Johnson & Johnson, Eisai Co. Ltd, AbbVie Inc., Bayer AG, Amgen Inc., Ipsen SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories Ltd., Novocure Ltd., Celldex Therapeutics Inc.
View The Full Anaplastic Astrocytoma Market Report:
Anaplastic Astrocytoma Market Top Region By Revenue And Market Share
North America was the largest region in the anaplastic astrocytoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaplastic astrocytoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
